This review comments on and summarizes five expert presentations and reports made at a meeting hosted by the World Health Organization (WHO) in Lyon, France, 12-14 June 2006, related to iron and folate supplementation and their interactions with infection. The meeting was called because of the mortality implications of the Pemba iron study and the possible need to change WHO policy as soon as possible. Six tabled presentations were reviewed. A majority of these expert reviews regarded the Pemba study as indicating a specific adverse interaction between iron supplementation and malaria. A majority regarded such an effect as already reviewed, demonstrated, and predicted in existing literature published prior to the Pemba study. A majority concluded that there was a risk of malarial morbidity associated with oral iron supplementation. A majority made recommendations for change, indicating either that the 1998 WHO/UNICEF recommendation for iron supplementation in malarious areas should be suspended pending further research or that it should be stopped. A majority felt that folate supplementation was a less likely cause of the Pemba result; two mentioned the interference of oral folate with antifolate antimalarials; a majority suggested suspension of folic acid supplementation to children in malarious areas. Only one presentation argued for net population benefits of folate and none for iron.
Preamble and terms of reference
The lack of clinical effect, either way, of supplementation in the Nepal study [1] , although highlighting what can, in this review, be called the "Pemba effect" [2] , does not indicate the need for a precipitate change in policy for nonmalarious areas. So, this review will concentrate on implications for iron (and folate) in malarious areas.
On looking at the papers on iron and infection from this meeting hosted by the World Health Organization (WHO) in Lyon, France, 12-14 June 2006 [3] [4] [5] [6] [7] [8] , I have concerns that the key questions raised by the Pemba study [2] and in previous reviews [9] [10] [11] [12] , which prompted this meeting and were explicitly discussed in the recent WHO/UNICEF Innocenti meeting, "Micronutrients for Health of Children and Mothers" in Florence, 17-20 April 2005 [13] , are not given sufficient prominence in the presentation briefs. Rather there is much theoretical emphasis, and the structure and agenda of the rest of the meeting presumptively emphasized and speculated on benefits iron might have and ways and means of delivering it.
This slant is consistent with the guiding spirit of the related International Life Sciences (ILSI)/UNICEF/ WHO/US Agency for International Development (USAID) meetings on iron previously attended by this participant (the first of these held in the offices of ILSI in Washington, DC, in 1999, which led to the "INACG Consensus Statement. Safety of iron supplementation programs in malaria-endemic regions. Washington:
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Comments on background papers than taken seriously. As shown in a previous review [12] , my evidence-based opinion would be in the middle between the two poles expressed by colleagues in the Lyon meeting, so although I hope to emphasize both benefits and risks, I would also hope to be evenhanded in discussion of these papers.
Given the literature, the following three questions relate mainly to malarious areas: » Does iron supplementation have detectable adverse effects in malarious areas? This means not just specific malarial morbidity and mortality, but global systematic measurement of all morbidity and mortality (malaria has an associated effect on other infections, especially respiratory ones), such as has only been carried out in one study prior to the Pemba study [16, 17] . » Does iron supplementation have detectable beneficial effects in malarious areas, apart from raising mean hemoglobin by 1 to 1.5 g/dL? The latter is simply a laboratory measurement, and lower levels have been associated with lower risk of hospital admission in malarious areas. » Does any organization, international, national, industrial, or nongovernmental, have the ethical right to recommend an elective program of community pharmacological intervention (i.e., higher intakes of iron than present in current diets) that carries a significant risk of serious adverse effects (including mortality) with or without benefit? The first two questions are not equal, hence the third. As Dr. Tielsch has succinctly put it in discussion at the Florence meeting [13] , "Adverse effects trump beneficial ones, " and even more so when there is an elective program. Also, in terms of adverse effects, the Pemba effect is clearly in a different ballpark from those connected, for example, with the fluoridization of drinking water, thus making the ethical question even more important.
From the point of view of legal process, it seems the only reason mass, unscreened iron supplementation is still even considered in malarious areas is that, as a supplement of an element already present in foodstuffs, it does not yet have the same stringent controls concerning adverse effects normally applied to pharmaceuticals (including iron) by bodies like the US Food and Drug Administration (FDA). Such legal limbo should not be allowed to obscure the ethical issue of pharmacological intervention with an element already known to be biologically toxic in a variety of situations.
In relation to the first two questions, the best way of addressing them properly is not by theoretical discussion of experimental laboratory work, much of which has been established in the literature already, or by massaging inadequate data from other studies, but by prospective, randomized, controlled clinical trials specifically designed to answer them. The chances of conducting any more trials are rapidly running out as a result of the Pemba study, because ethical boards may not approve further such trials. This trial was, after all, terminated because of adverse effects.
To the extent the first two questions have already been formally addressed in the literature, I do not apologize for the presumption of extracting from the abstract of my own review [12] of clinical trials prior to Pemba:
Oral iron has been associated with increased rates of clinical malaria (5 of 9 studies) and increased morbidity from other infectious disease (4 of 8 studies). In most instances, therapeutic doses of oral iron were used. No studies in malarial regions showed benefits [12] .
Not all of the studies with adverse effects, however, used higher dose supplementation.
Tabular review (Table 1)
To the extent that the first two iron questions are addressed in three tabled papers [3, 5, 6] prepared for the WHO meeting, I have extracted or quoted statements in tabular form for ease of comparison. With the agreement of the WHO organizers, I have included two other relevant tabled papers [7, 8] . Lack of context may result in meaning being altered by quotation, so I apologize if I have inadvertently misrepresented any particular "positions, " but the final edited papers (including one on folate) are available in this issue of the Food and Nutrition Bulletin for confirmation [3] [4] [5] [6] [7] [8] .
I have ranked position statements from "can do" (i.e., perceptions of the evidence and issues in favor of iron supplementation in the top row) to "cannot do" (i.e., perceptions of the evidence and issues against or showing caution in relation to iron supplementation in malarious areas clearest in the bottom row) on five key issues and sources of evidence: » Whether iron contributed to the adverse malaria effects in the Pemba study [2] (including, in one paper [8] , doubt as to whether the malaria effect was significant); » Existing reviews of iron-malaria interaction; » Authors' own review of the iron-malaria interaction; » Overall conclusions as to the risk of increased malarial morbidity with oral iron supplementation (this does not just mean incidence and does include evidence that other infections may be increased in malarious areas); » Recommendations concerning iron supplementation in malarious areas, such as: carry on supplementing, immediate moratorium on WHO policy in malarious areas, targeted treatment of iron deficiency or anemia, targeted supplementation, or more research.
Ranking of authors in terms of their positions in table 1 is clearly consistent for relevant responses on all these five issues and sources of evidence. Given that this is largely dependent on the answer to the first question, this is to be expected, but secondary citation of existing literature ("meta-analysis" or any other reports) ought to be accurate and consistent. Any observation that this is not quite the case, even to the extent of noncitation, could suggest a subjective element in position. For instance, one author [8] presented two previous meta-analysis studies [11] and Shankar et al. (1999, unpublished) , as "a summary of the evidence prior to the two recent supplementation trials, " apparently arguing that they did not find "statistically significant" evidence of adverse interaction between iron and malaria, thus presumably not predicting or prefiguring a Pemba/Nepal outcome. This position, however, meant not citing another meta-review [12] available to all participants. Other reviewers read significant adverse messages into both the Gera and Sachdev and the Shankar et al. reviews. My reading of the latter two sets of meta-analyses agrees with the latter views in that there was evidence of adverse effects, although there were underlying analytical and data-entry flaws in both, tending to underestimate actual effects. The Gera and Sachdev review was available to all participants. The Shankar et al. unpublished review was also available to the Lyons meeting. This author expressed oral and written reservations at the 1999 ILSI meeting (see above) at which it was presented.
These differences in perception of the existing literature are consistent with discussions and conclusions in previous meetings (1999, 2000, and 2005 ; see above [13] [14] [15] ). All opinions are to a certain extent subjective, but subjectivity may be a more useful adjunct in the ethical discussion. My own opinion on the main evidence existing in the literature prior to but raised again by the Pemba and Nepal studies is extensively laid out in my most recent review [12] and is merely confirmed by these two recent studies, with the additional specter of measurable mortality. That review would put my position roughly in the middle, between Lynch et al. [7] and Hershko [5] on my own arbitrary ranking.
To summarize assessments of evidence and conclusions, the balance of opinion is that there is a serious adverse effect of iron supplementation relating to malarial and other infections in the Pemba study and that this contrasts with the Nepal study and is consistent with preexisting reviews.
Is iron deficiency protective? Does supplementation in deficiency help?
The really important yet unanswered iron/malaria subissues revisited by Pemba and in several of the reviews in this issue are the two related but distinct questions of whether iron deficiency has a net protective or deleterious effect, in some or all, in the Pemba-like environment, and whether iron supplementation benefits some or all of those who are iron deficient. There is a range of opinion among authors who comment on these two questions from "iron good" to "iron bad, " but the underlying dynamics are far from clear, and the meager evidence on the respective questions seems, on the face of it, to point to quite opposite physiological conclusions.
Does iron deficiency have a protective or a deleterious effect in the Pemba-like environment?
Prentice et al. [6] usefully lists the few observational studies in his table 1, which might inform on this first question [16, [18] [19] [20] . Three out of four studies were consistent with a protective effect of iron deficiency without supplementation, but all were beset with confounding factors, even the most recent and convincing study [20] .
Does iron administration benefit some or all iron-deficient populations in malarious regions?
This second question might seem to be answered by the Pemba "iron-deficient" subset, but this subset was not randomly selected, thus allowing the risk of confounding factors, as with observational biological studies. We do not know in detail the relative hemoglobinopathy makeup of this subset or of the other ones. α-Thalassemia, for instance, not only has a complex interaction with iron and malaria [21] , but also biochemically and hematologically mimics iron deficiency [22] . On the other hand, sickle cell trait is extremely common in this part of Africa, but the only study that reports on malarial morbidity in this condition when combined with iron-supplementation shows an adverse interaction in the heterozygote [23] , unlike α-thalassemia. For all we know, sickle trait may have been relatively concentrated in the "non-iron-deficient" group compared with thalassemia, which with its tendency to mimic iron deficiency may have segregated in the "iron-deficient group. " This is, of course, speculation, but it highlights the fact that not enough is known about this unexpected subgroup effect to form the basis of yet more intervention policy, albeit targeted.
The available evidence does not allow us to draw clear conclusions yet either way, but good knowledge would need to be the basis of a change in policy toward targeting either for supplementation or for treatment. The fact that this subgroup did appear to benefit, however, does provide a window and the ethical basis for a randomized, controlled trial based on targeting S554 S. Oppenheimer only individuals with demonstrable iron deficiency (and not preselected by anemia). This would need to take account of both age and immunity, preferably using an age cohort. Trials targeting on evidence of iron deficiency, with adequate knowledge of hemoglobinopathies and adequate power to detect subgroup disadvantage and risk, would seem to be indicated.
Targeting on low hemoglobin would seem to be unwise, even in the present state of knowledge. All those previous studies of oral iron supplementation, which showed increase in malaria, significant or otherwise, were in effect targeted anemia treatment trials [12] . In fact, the only oral study prior to Pemba that did not target anemia in malarious areas was the Menendez early infancy cohort trial, which incidentally did not show any adverse malaria effects [24] . This may be coincidence, but targeting on anemia would seem to be a dangerous bias, potentially recruiting more cases of active malaria than otherwise and incorrectly identifying iron deficiency. In any case, most of the intervention studies that showed adverse effects of malaria were selecting for anemia and were essentially anemia treatment trials. It would be extraordinary if a repeat of this process of selection received ethical board approval.
Benefit
None of the five authors claim that Pemba or Nepal or any other individual clinical trials in malarious areas resulted in a significant overall reduction in infectious morbidity or mortality. Three authors rightly raised the Pemba evidence for subgroup benefit. The potential psychological benefits of iron are discussed in other papers in this issue, but the only prospective cognitive function study of iron supplementation conducted in a malarious area (in current literature) had arguably adverse effects on total fixation time [25] . The question of whether there is any other benefit from iron supplementation is, however, clouded by the issue of hemoglobin response, which is frequently promoted as an unalloyed clinical benefit of iron. The problem is that it is only a laboratory measurement, and several authors in the Belmont meeting (2000, see above [15] ) recently questioned the evidence base for this claim, even to the extent that a higher than average hemoglobin could be a negative predictor of childhood outcome in malarious areas [26] . The relationship between hemoglobin and morbidity and mortality in malarious areas therefore needs to be discussed.
Hemoglobin levels and morbidity in malarious regions
The importance of net positive hemoglobin response in randomized, controlled trials of oral iron in malarious areas is stressed as a benefit by Stoltzfus et al. [8] and Prentice et al. [6] . Hemoglobin concentration would seem to be regarded in this instance as a general health indicator, rather like height-for-age, weight-for-age, weight-for-height, and mid-upper-arm circumference, which in children in the tropics tend to have consistently positive relationships with survivorship. There are a number of pieces of evidence that bring this nutritional assumption of benefit into doubt for hemoglobin in the tropics.
First of all, the hemoglobin of children supplemented with iron is systematically lower than that of placebo controls in the presence of evidence for malaria [17] , so although the net mean hemoglobin may be higher in the supplemented group (and nearly always is), when the children actually have malaria, a cause of life-threatening anemia, this advantage seems to be reversed.
Then there are the few observational studies in which baseline hemoglobin is used as a predictor of outcome in nonsupplemented children in malarious areas. In these instances, lower mean birth hemoglobin levels at the start of the study in unsupplemented children protect to a sizable degree both against malaria and the risk of hospital admission [16, 17] .
Then there are the genetic causes of mild anemia, which significantly protect against serious infectious morbidity (malarial and otherwise) [21, 27] . These are, on a cross-sectional basis, arguably more important background causes of mild anemia in malarious areas than either malaria or iron deficiency [28, 29] . Yet, with the exception of the rarer specific sickle and β-thalassemia major homozygote conditions, they are not causes of severe, life-threatening anemia.
Then there is the question of the linearity of the relationship between anemia and risk of death. In general, the improvement of hemoglobin in supplementation trials in malarious regions is of the order of 1 to 1.5 g/dL. For this to translate into significant reduction of mortality due to anemia, the relationship between anemia and mortality would need to extend into the bulk of the population in the middle of the bell curve, as well as at the left-hand tail of the distribution. As mentioned above, the advantage of higher hemoglobin may not be there in that tail in the case of malaria.
The question of benefits that might accrue from raising average hemoglobin in children by iron supplementation was addressed formally by Brabin et al. [26] , at the WHO/UNICEF Belmont meeting (2000, see above [15] ). In the review it was pointed out that, in general, "mortality due to malarial severe anaemia is greater than due to iron deficiency anaemia. " Furthermore, the regression curve between fatality and hemoglobin was U-shaped, with the optimum hemoglobin for survivorship at 6 to 7 g/dL [26] . This outcome could hardly be taken as an endorsement of the need to raise S555 Comments on background papers mean population hemoglobin above 10 g/dL. To quote: "The data suggested little if any dose-response relating increasing hemoglobin level (whether by mean value or selected cut-off values) with decreasing mortality. " [26] Although there was agreement that severe anemia was associated with mortality, the titration of the threshold of this effect was constrained by available data and the somewhat arbitrary cutoff of 5 g/dL in most of the primary sources.
I can add a personal observation on this point, having personally treated hundreds of cases of severe malarial anemia and proportionately fewer cases of non-malarious severe iron-deficiency anemia over 17 years in the tropics. As a general rule, afebrile anemia admissions with hemoglobin > 3 g/dL had a good prognosis. But if they had less than 3 g/dL hemoglobin, were febrile, had heart failure, or had signs of altered consciousness, then minutes counted in the initiation of transfusion and diuretics, combined with antimalarial treatment.
In passing, while on this subject, I cannot agree with the practical implications of Prentice's statement that "the key cause of malaria-induced anemia is a maldistribution of iron and suppression of erythropoiesis rather than an exacerbation of gross iron deficiency" [6] in terms of morbidity and mortality. The key cause of malaria-induced anemia from the point of view of the infant's survival is not so much the failure to recycle iron, but the rapid logarithmic phase of red cell destruction in acute malaria both in the spleen and in the peripheral circulation, which takes hemoglobin down below 4 g/dL in a matter of several days and then kills. From my own research and observations in infants under 1 year of age [16, 17] , it is clear that it is less the failure of erythropoiesis that is the problem in this situation than the inability of the marrow to turn out more than 1 g/dL/week of hemoglobin, even when working flat out.
Summary of assessments of estimable risk and benefit in malarious zones like Pemba
No author specifically claimed that the benefits of universal iron supplementation (with or without folate) outweighed the risks in a malaria-endemic situation like Pemba. Only two authors claimed any potential benefit (apart from cognitive) in the universal scenario. This benefit was expected from the net mean increase in hemoglobin. Several authors questioned the evidence for linking this laboratory change to a measurable clinical benefit. A previous review in this series of discussions sponsored by WHO, given at the 2000 Belmont meeting, had rejected the claim [26] . No author claimed this scenario was risk free. Putting these together, there was a consensus that benefit did not outweigh risk in this particular scenario of iron supplementation.
As far as the substudy/subgroup (evidence of iron deficiency) benefit versus risk was concerned, there was generally more optimism. However, the assessments and recommendations ranged from no added iron at all, through caution resulting from insufficient available knowledge, to a view that this finding could form the basis for a hemoglobin-only screening and supplementation policy, with the attendant risks of preferentially selecting malaria cases.
Ethics
We turn now to the question "Do we have the ethical right to recommend an elective program of community pharmacological intervention (i.e., higher intakes of iron than recommended in normal diets) that carries a significant risk of adverse effects (let alone mortality) with or without benefit?"
The only author who specifically addresses the hypothetical ethical dilemma of whether elective nutritional interventions can be ethically justified in the presence of significant risk (in the broadest sense of "significant") made several explicit statements, which usefully allow further discussion. I quote these here (my italics), not to make any specific comment on the ethical issues in a randomized, controlled trial on targeting, based on the Pemba outcome, but to explore ethical attitudes to risk and benefit in an elective situation:
Ethical considerations in targeting
A final but important note about our CEA [cost-effectiveness analysis] of targeting is that we valued all adverse events equally, whether prevented by IFA supplementation or caused by IFA supplementation. This is reasonable from a purely cost perspective, but depending on one's ethical perspective, one might view a death from other causes in the absence of iron supplementation differently from a death attributable to IFA supplementation as a public health intervention. Many public health interventions confer risk to a minority while providing net benefit to the population as a whole (e.g., folic acid fortification…) For this specific example, based on the Pemba scenario, targeting is cost-effective (relative to universal supplementation) and also removes any ethical dilemma [8] .
As Stoltzfus says, an ethical perspective is important and hers is a nutritional one: "Current iron-supplementation programs are motivated by concern for children's well-being and development, rather than reductions in severe infectious morbidity" [8] . However infectious morbidity and mortality are clearly incompatible with a state of 'well-being' .
Given the demonstrable adverse clinical outcomes from supplementation, the ethical perspective should be a clinical one. There is an ancient clinical maxim S556 S. Oppenheimer drummed into doctors: primum non nocere (first do no harm). This is part of what drives the stringent rules of the FDA in the United States. For any clinical intervention, whether elective or emergency, potential benefit has to outweigh potential risk to a considerable degree, rather than being just over par. A small excess of benefit over risk would still be unacceptable, even when treating a sick individual with fully informed consent. This means that adverse events cannot be regarded as equivalent when resulting from intervention as opposed to prevented by intervention.
The nearest equivalent intervention for which the FDA imposes ethical standards is immunization. A document published by the British Medical Association gives guidelines relating to known significant risk: "For all childhood vaccine-preventable diseases, the risk of complications with the natural infections is very much greater than the risk of a serious adverse reaction following the vaccine" [30] . Generally, the ratio between the adverse effects of not having a vaccine and having it vary between 1:100 and 1:1,000. This comfortably low risk-to-benefit ratio changes to 1:70 for convulsions in the exceptional case of pertussis vaccine [30] .
Like vaccination, mass supplementation has several ethical bars against accepting any but the smallest amount of risk. First, it is not only elective but has no formal consent; second, the individuals in the population have to be presumed well prior to intervention (i.e., not actually sick).
Review of recommendations
There was a range of recommendations with positions predictable on the relevant and relative assessments of evidence. Apparently, none regarded the status quo (present WHO recommendations [31] ) as completely satisfactory, although this is not completely clear in one instance. At the "cannot do" end of the spectrum, one author [3] was against iron supplementation (above that supplied by an adequate diet) at all in infection, even in severe cases of anemia. This position was followed closely by another who stated "iron depletion may have a defensive role…and may be perturbed by the nonselective administration of iron to patients who would not benefit from a treatment they do not need in the first place. " [5] At the "can do" end of the spectrum, although not explicitly stated, one may infer that the author [8] saw no reason to change the present policy at this stage, but did recommend further funded research on supplementation, including, but not exclusive to, exploring targeted supplementation. Targeting and screening were incidentally mentioned by four of five authors, presumably therefore a consensus on consideration. Prentice et al. [6] gave no proscription on the present policy, but stated:
We tentatively conclude that, if it is to be recommended, universal iron supplementation in malarious areas should only be considered in conjunction with some form of prophylaxis (e.g., intermittent preventive therapy [IPT]), or in the context of good health services with ready access to facilities for malaria diagnosis and treatment. An alternative approach would be to screen for anemia and target supplementation only to anemic children. With regard to treatment, there is good evidence that iron supplementation should be withheld until the treatment schedule is complete both because iron may inhibit treatment and because the absorption of oral iron is blocked by the inflammatory response [6] .
I have quoted this in full, because of the important discussion items it raises: » Adequate antimalarial cover is often specified as a prerequisite in recommendations. However, can such universal antimalarial cover be honestly guaranteed? Routine prophylaxis also increases the risk of drug resistance. » Is hemoglobin an adequate screening measurement, in view of the multifactorial nature of the anemia and risk of selecting for malaria cases, as has happened before in several anemia trials with adverse outcomes? » The feasibility issues of delayed iron therapy in busy clinics in malarious areas.
In the middle rank, from Lynch et al. [7] , we have the only clear and practical advice for WHO and UNICEF, which I quote in full and endorse, although the details of modification need to be discussed and the questions on human iron deficiency and supplementation in iron deficiency remain unanswered, or at least incompletely answered:
As a result of the observations made in Pemba, recommendations for strategies to control and prevent iron deficiency in children should be revised. A single strategy for different parts of the world is no longer likely to be satisfactory. Integration with other health-related strategies, particularly malaria control programs, will be essential. It would be prudent to modify the current recommendations immediately on at least a provisional interim basis while recognizing that further research is needed to identify optimal approaches. In making these adjustments and designing further research, consideration should be given to a better understanding of optimal iron status in various environments and methods for quantifying optimal iron status, as well as strategies for delivering additional iron safely [7] .
Folic acid supplementation in Pemba and
Nepal (Table 2) I have provided a similar table (table 2) to that for iron in order to extract the opinions of other authors [4] [5] [6] [7] [8] , where given. There is little to add to this admirable review of the literature, except to summarize that two S557 Comments on background papers , Pemba] appears greater than the benefit in the current state of knowledge"
"There is little direct evidence of widespread folate deficiency, and the benefit of folic acid added to iron supplements given to these infants and children awaits the results of more extensive trials"
"It follows then that consideration be given to excluding folic acid from the WHO recommendation" plus suggestions for further research and knowledge SP, sulfadoxine-pyrimethamine .
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S. Oppenheimer of three authors in this issue who did comment [4, 7, 8] felt that folate was not justified in the WHO recommendation, on questions of need or benefit-versus-risk arguments. The single dissenting author, Stoltzfus et al. [8] , while agreeing there were risks, argued that they were outweighed by the benefits. On the issue of whether the Pemba effect was mainly due to folate rather than iron, the folate review author, Metz [4] , was in a minority of one out of three, although it is acknowledged that the lack of requisite cells made this issue difficult to judge.
